The Influence of Residual Nor-β-CFT in 11C CFT Injection on the Parkinson Disease Diagnosis A 11C CFT PET Study
The Influence of Residual Nor-β-CFT in 11C CFT Injection on the Parkinson Disease Diagnosis A 11C CFT PET Study
复制标题
DOI：
10.1097/rlu.0b013e31824c5fae
复制
发表时间：
2012-08-01
影响因子：
10.6
通讯作者：
Zhang, Xiangsong
中科院分区：
文献类型：
--
作者：
Huang, Tingting;Wang, Hongliang;Zhang, Xiangsong
目的：全自动合成C-11标记的2-β-甲氧基-3-β-(4-氟苯基)托烷(C-11 CFT)作为多巴胺转运体正电子发射断层扫描(PET)示踪剂，采用Sep-Pak纯化方法，不能将C-11 CFT与Nor-β-CFT分离，导致在最终的C-11 CFT注射中残留前体Nor-β-CFT。本研究的目的是评估C-11 CFT注射剂中残留的Nor-β-CFT前体对帕金森病(PD)诊断结果的影响。方法：使用不同化学量(0.10、0.20、0.25和0.30 mg)的Nor-β-CFT经Sep-Pak纯化后自动合成C-11 CFT。根据放射合成中给予不同剂量的Nor-β-CFT，临床疑似PD患者25例，随机分为4组：0.10 mg、0.20 mg、0.25 mg、0.30 mg，分别为5、9、5、6例。正常对照组给予0.10 mg的Nor-beta-CFT，包括2名志愿者。采集受试者的脑PET图像后，绘制纹状体和小脑的感兴趣区，并计算这些区域的标准摄取值。结果：给予前体Nor-β-CFT 0.25 mg，可在较短的合成时间内获得高放化产率(59.4%)和高放化纯度的C-11 CFT。4组疑似帕金森病患者纹状体与小脑的C-11CFT标准摄取值比值无统计学差异(P>；0.05)。但可疑PD组与对照组比较，差异有统计学意义(P<；0.05)。不同剂量组C-11CFTPET诊断PD与临床诊断结果的符合率均在80%以上，但符合率差异无统计学意义(P=0.955)。结论：用0.25mgNor-β-CFT和SEP-Pak纯化，可以简便、快速、高效地自动合成C-11CFT，为常规的PDPET显像提供了足够的放射性。C-11 CFT注射剂中残留的Nor-β-CFT不抑制C-11 CFT与多巴胺转运体的结合，也不影响PD的PET诊断结果。
Purpose: Fully automated synthesis of C-11-labeled 2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane (C-11 CFT) as a dopamine transporter positron emission tomography (PET) tracer is performed with Sep-Pak purification, which cannot separate C-11 CFT from nor-beta-CFT and will result in the residual precursor nor-beta-CFT in the final C-11 CFT injection. The aim of this study is to estimate the influence of the residual precursor nor-beta-CFT in the C-11 CFT injection on the Parkinson disease (PD) diagnosis results.Methods: Automated synthesis of C-11 CFT was performed using the different chemical amounts (0.10, 0.20, 0.25, and 0.30 mg) of nor-beta-CFT with Sep-Pak purification. According to the given different amounts of nor-beta-CFT in the radiosynthesis, clinically suspected 25 PD patients were randomly divided into the following 4 groups: 0.10 mg, 0.20 mg, 0.25 mg, and 0.30 mg, which had 5, 9, 5, and 6 cases, respectively. A normal control group with 0.10 mg of nor-beta-CFT included 2 volunteers. After the brain PET images of the subjects were acquired, the regions of interests of striatum and cerebellum were drawn, and the standard uptake values of these regions were calculated. Finally, comparing the F-18 FDG PET and clinical diagnosis, the coincidence rates of C-11 CFT PET imaging for PD patients were determined.Results: Given 0.25 mg of the precursor nor-beta-CFT, high radiochemical yield (59.4%) and high radiochemical purity of C-11 CFT were obtained using Sep-Pak purification within a short synthesis time. The C-11 CFT standard uptake value ratios of striatum to cerebellum had no statistically significant difference (P > 0.05) between the 4 suspected PD groups. However, there was statistically significant difference (P < 0.05) between the suspected PD groups and the control group. Also, the coincidence rates between the PD diagnosis using C-11 CFT PET imaging for different dose groups and the final clinical diagnosis result were greater than 80%, but difference between the coincidence rates was not statistically significant (P = 0.955).Conclusions: A simple, rapid, and efficient automated synthesis of C-11 CFT using 0.25 mg of nor-beta-CFT with Sep-Pak purification is afforded, providing enough radioactivity for PD PET imaging routinely. The residual nor-beta-CFT in the C-11 CFT injection is not inhibit C-11 CFT binding to dopamine transporter, and also has no influence on PET diagnosis results of PD.